Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

Influence of SLCO1B3 genetic variations on tacrolimus pharmacokinetics in renal transplant recipients.

Boivin AA, Cardinal H, Barama A, Naud J, Pichette V, Hébert MJ, Roger M.

Drug Metab Pharmacokinet. 2013;28(3):274-7. Epub 2012 Nov 13.

2.

Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients.

Miura M, Satoh S, Inoue K, Kagaya H, Saito M, Inoue T, Suzuki T, Habuchi T.

Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9. Epub 2007 Sep 29.

PMID:
17906856
3.

Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients.

Roy JN, Barama A, Poirier C, Vinet B, Roger M.

Pharmacogenet Genomics. 2006 Sep;16(9):659-65.

PMID:
16906020
4.

Influence of SLCO1B3 haplotype-tag SNPs on docetaxel disposition in Chinese nasopharyngeal cancer patients.

Chew SC, Sandanaraj E, Singh O, Chen X, Tan EH, Lim WT, Lee EJ, Chowbay B.

Br J Clin Pharmacol. 2012 Apr;73(4):606-18. doi: 10.1111/j.1365-2125.2011.04123.x.

5.

Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms.

Op den Buijsch RA, Christiaans MH, Stolk LM, de Vries JE, Cheung CY, Undre NA, van Hooff JP, van Dieijen-Visser MP, Bekers O.

Fundam Clin Pharmacol. 2007 Aug;21(4):427-35.

PMID:
17635182
6.

Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.

Tsuchiya N, Satoh S, Tada H, Li Z, Ohyama C, Sato K, Suzuki T, Habuchi T, Kato T.

Transplantation. 2004 Oct 27;78(8):1182-7.

PMID:
15502717
7.
8.

Organic anion transporting polypeptide 1B1 (OATP1B1) and OATP1B3: genetic variability and haplotype analysis in white Canadians.

Boivin AA, Cardinal H, Barama A, Pichette V, Hébert MJ, Roger M.

Drug Metab Pharmacokinet. 2010;25(5):508-15. Epub 2010 Sep 22.

9.

Influence of SLCO1B3 gene polymorphism on the pharmacokinetics of digoxin in terminal renal failure.

Tsujimoto M, Dan Y, Hirata S, Ohtani H, Sawada Y.

Drug Metab Pharmacokinet. 2008;23(6):406-11.

10.

Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients.

Cho JH, Yoon YD, Park JY, Song EJ, Choi JY, Yoon SH, Park SH, Kim YL, Kim CD.

Transplant Proc. 2012 Jan;44(1):109-14. doi: 10.1016/j.transproceed.2011.11.004.

PMID:
22310591
11.

Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients.

Anglicheau D, Verstuyft C, Laurent-Puig P, Becquemont L, Schlageter MH, Cassinat B, Beaune P, Legendre C, Thervet E.

J Am Soc Nephrol. 2003 Jul;14(7):1889-96.

12.

Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.

Zhang X, Liu ZH, Zheng JM, Chen ZH, Tang Z, Chen JS, Li LS.

Clin Transplant. 2005 Oct;19(5):638-43.

PMID:
16146556
13.

Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.

Zuo XC, Ng CM, Barrett JS, Luo AJ, Zhang BK, Deng CH, Xi LY, Cheng K, Ming YZ, Yang GP, Pei Q, Zhu LJ, Yuan H, Liao HQ, Ding JJ, Wu D, Zhou YN, Jing NN, Huang ZJ.

Pharmacogenet Genomics. 2013 May;23(5):251-61. doi: 10.1097/FPC.0b013e32835fcbb6.

PMID:
23459029
14.

Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.

Shi Y, Li Y, Tang J, Zhang J, Zou Y, Cai B, Wang L.

Gene. 2013 Jan 10;512(2):226-31. doi: 10.1016/j.gene.2012.10.048. Epub 2012 Oct 26.

PMID:
23107770
15.

Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.

Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, Weimar W, van Gelder T.

Clin Pharmacol Ther. 2003 Sep;74(3):245-54.

PMID:
12966368
16.

A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.

Elens L, Bouamar R, Hesselink DA, Haufroid V, van der Heiden IP, van Gelder T, van Schaik RH.

Clin Chem. 2011 Nov;57(11):1574-83. doi: 10.1373/clinchem.2011.165613. Epub 2011 Sep 8.

17.

CYP3A4/5 polymorphisms affect the blood level of cyclosporine and tacrolimus in Chinese renal transplant recipients.

Li DY, Teng RC, Zhu HJ, Fang Y.

Int J Clin Pharmacol Ther. 2013 Jun;51(6):466-74. doi: 10.5414/CP201836.

PMID:
23557867
18.

Frequencies of single-nucleotide polymorphisms of SLCO1A2, SLCO1B3 and SLCO2B1 genes in a Finnish population.

Laitinen A, Niemi M.

Basic Clin Pharmacol Toxicol. 2011 Jan;108(1):9-13. doi: 10.1111/j.1742-7843.2010.00605.x.

19.
20.

Association between tacrolimus concentration and genetic polymorphisms of CYP3A5 and ABCB1 during the early stage after liver transplant in an Iranian population.

Rahsaz M, Azarpira N, Nikeghbalian S, Aghdaie MH, Geramizadeh B, Moini M, Banihashemi M, Darai M, Malekpour Z, Malekhosseini SA.

Exp Clin Transplant. 2012 Feb;10(1):24-9.

Supplemental Content

Support Center